{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:32:08Z","timestamp":1792524728575,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41582-024-00957-9","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T07:02:06Z","timestamp":1712127726000},"page":"313-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Approval of omaveloxolone for Friedreich ataxia"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1657-7368","authenticated-orcid":false,"given":"Sylvia","family":"Boesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-8630","authenticated-orcid":false,"given":"Elisabetta","family":"Indelicato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"957_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2023.2276758","volume":"32","author":"S Boesch","year":"2023","unstructured":"Boesch, S. & Indelicato, E. Experimental drugs for Friedrich\u2019s ataxia: progress and setbacks in clinical trials. Expert Opin. Investig. Drugs 32, 967\u2013969 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"957_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01475-9","volume":"15","author":"E Indelicato","year":"2020","unstructured":"Indelicato, E. et al. Onset features and time to diagnosis in Friedreich\u2019s ataxia. Orphanet J. Rare Dis. 15, 198 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"957_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.29687","volume":"39","author":"E Indelicato","year":"2024","unstructured":"Indelicato, E. et al. Predictors of survival in Friedreich\u2019s ataxia: a prospective cohort study. Mov. Disord. 39, 510\u2013518 (2024).","journal-title":"Mov. Disord."},{"key":"957_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/21678707.2018.1409109","volume":"6","author":"E Indelicato","year":"2018","unstructured":"Indelicato, E. & B\u00f6sch, S. Emerging therapeutics for the treatment of Friedreich\u2019s ataxia. Expert Opin. Orphan Drugs 6, 57\u201367 (2018).","journal-title":"Expert Opin. Orphan Drugs"},{"key":"957_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch, D. R. et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). Ann. Neurol. 89, 212\u2013225 (2021).","journal-title":"Ann. Neurol."},{"key":"957_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.29286","volume":"38","author":"DR Lynch","year":"2023","unstructured":"Lynch, D. R. et al. Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension. Mov. Disord. 38, 313\u2013320 (2023).","journal-title":"Mov. Disord."},{"key":"957_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/acn3.51897","volume":"11","author":"DR Lynch","year":"2024","unstructured":"Lynch, D. R. et al. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Ann. Clin. Transl. Neurol. 11, 4\u201316 (2024).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"957_CR8","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1093\/hmg\/ddg349","volume":"12","author":"G Karthikeyan","year":"2003","unstructured":"Karthikeyan, G. et al. Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum. Mol. Genet. 12, 3331\u20133342 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"957_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2015.08.003","volume":"25","author":"I Singh","year":"2015","unstructured":"Singh, I. et al. Investigation of mitochondrial DNA variations among Indian Friedreich\u2019s ataxia (FRDA) patients. Mitochondrion 25, 1\u20135 (2015).","journal-title":"Mitochondrion"},{"key":"957_CR10","doi-asserted-by":"publisher","first-page":"1289027","DOI":"10.3389\/fnins.2023.1289027","volume":"17","author":"E Indelicato","year":"2023","unstructured":"Indelicato, E. et al. Skeletal muscle proteome analysis underpins multifaceted mitochondrial dysfunction in Friedreich\u2019s ataxia. Front. Neurosci. 17, 1289027 (2023).","journal-title":"Front. Neurosci."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00957-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00957-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00957-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:14:45Z","timestamp":1717492485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-024-00957-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1038\/s41582-024-00957-9","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"3 April 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.B. reports consultancy activity for VICO Therapeutics, REATA Pharmaceutics and Biogen, advisory board activity for REATA Pharmaceutics and Biogen, and honoraria from Ipsen, Merz Pharma, Abbvie, REATA Pharmaceutics and Biogen. E.I. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}